Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Odile Gayet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8635-3648; OpenAlex author ID A5004923572. Sources: OpenAlex.

Their work

Papers
29 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 6 papers · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 29

  1. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  2. The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70736↗
  3. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Co-author DOI 10.1016/j.ebiom.2023.104634↗
  4. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
  5. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  6. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… First author DOI 10.1016/j.tranon.2021.101315↗
  7. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  8. Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. Co-author DOI 10.1002/exp.20210003↗
  9. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. First author DOI 10.1016/j.annonc.2020.10.601↗
  10. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
  11. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  12. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Co-author DOI 10.3390/cancers13102473↗
  13. Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Auto… First author DOI 10.3390/cancers13236124↗
  14. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  15. Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100143↗
  16. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical s… Co-author DOI 10.1096/fj.202000363rr↗
  17. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Co-author DOI 10.1158/1078-0432.ccr-20-1232↗
  18. PML hyposumoylation is responsible for the resistance of pancreatic cancer. Co-author DOI 10.1096/fj.201901091r↗
  19. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). Co-author DOI 10.3389/fonc.2019.00475↗
  20. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  21. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based t… Co-author DOI 10.1038/s41598-018-26613-z↗
  22. Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.25745↗
  23. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  24. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  25. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  26. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  27. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗
  28. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  29. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nelson Dusetti · 27 shared papers, 2015–2026 · strength 2.93
  2. Juan Iovanna · 28 shared papers, 2015–2026 · strength 2.79
  3. Julie Roques · 15 shared papers, 2015–2026 · strength 1.74
  4. Nicolas Alejandro Fraunhoffer · 9 shared papers, 2020–2026 · strength 1.36
  5. Rémy Nicolle · 10 shared papers, 2017–2022 · strength 0.93
  6. Abdessamad El Kaoutari · 6 shared papers, 2020–2023 · strength 0.74
  7. Philippe Soubeyran · 5 shared papers, 2018–2026 · strength 0.73
  8. Brice Chanez · 3 shared papers, 2022–2026 · strength 0.55
  9. Marc F. Giovannini · 9 shared papers, 2015–2022 · strength 0.55
  10. Analía Meilerman Abuelafia · 4 shared papers, 2020–2022 · strength 0.54
  11. Jerome F. Cros · 5 shared papers, 2019–2022 · strength 0.50
  12. Marine Gilabert · 9 shared papers, 2015–2021 · strength 0.47
  13. Pauline Duconseil · 8 shared papers, 2015–2021 · strength 0.43
  14. Raul A. Urrutia · 5 shared papers, 2017–2022 · strength 0.42
  15. Gwen Alyce Lomberk · 5 shared papers, 2017–2022 · strength 0.42
  16. Céline Loncle · 8 shared papers, 2015–2021 · strength 0.40
  17. Eduardo Chuluyán · 3 shared papers, 2020–2022 · strength 0.39
  18. Benjamin Bian · 6 shared papers, 2016–2019 · strength 0.36
  19. Rawand Masoud · 3 shared papers, 2019–2023 · strength 0.32
  20. Alice Carrier · 3 shared papers, 2019–2023 · strength 0.32
  21. Olivıer Turrini · 7 shared papers, 2015–2018 · strength 0.30
  22. Mehdi Ouaïssi · 7 shared papers, 2015–2017 · strength 0.29
  23. Sharon Prince · 1 shared paper, 2025 · strength 0.27
  24. Karabo Serala · 1 shared paper, 2025 · strength 0.27
  25. Véronique Secq · 6 shared papers, 2015–2018 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.